[Management of Parkinson's disease in 2009]
- PMID: 19772196
[Management of Parkinson's disease in 2009]
Abstract
The cause of Parkinson's disease remains unknown and no cure or prevention exists so far. Levodopa remains by far the most potent symptomatic therapy, but induces side-effects such as motor fluctuations and abnormal movements, which can somewhat be counterbalanced by optimizing levodopa plasma levels or acting at receptors level with long half-life dopamine agonists. In severe cases, functional surgery with deep brain stimulation can be offered. Some non-dopaminergic symptoms like dementia, freezing, postural instability or dysautonomia do not respond to dopaminergic drugs and need special care.
Similar articles
-
Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia.Clin Neuropharmacol. 2008 Jan-Feb;31(1):51-6. doi: 10.1097/WNF.0b013e318065b088. Clin Neuropharmacol. 2008. PMID: 18303491 Review.
-
Should levodopa be used anymore?Acta Neurol Belg. 2002 Dec;102(4):163-6. Acta Neurol Belg. 2002. PMID: 12534242 Review.
-
Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.Eur Neurol. 2008;60(2):57-66. doi: 10.1159/000131893. Epub 2008 May 15. Eur Neurol. 2008. PMID: 18480609 Review.
-
Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.J Neurol. 2002 Sep;249 Suppl 2:II25-9. doi: 10.1007/s00415-002-1205-3. J Neurol. 2002. PMID: 12375060 Review.
-
Treatment of Parkinson's disease in Thailand: review of the literature and practical recommendations.J Med Assoc Thai. 2009 Jan;92(1):142-54. J Med Assoc Thai. 2009. PMID: 19260256 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical